NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...
Stifel Nicolaus Sticks to Its Buy Rating for Cipher Pharmaceuticals (CPHRF)
Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Cipher Pharmaceuticals (CPHRF – Research Report) today and set a price ...
Stifel Nicolaus Keeps Their Buy Rating on Savaria (SIS)
Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Savaria (SIS – Research Report) today and set a price target of ...
Stockhouse14d
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Coinbase Global, Inc. Investors to Inquire About Securities Class Action Investigation - COIN
New York, New York--(Newsfile Corp. - September 6, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ...
Nasdaq24d
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular ...
kalkinemedia24d
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated t... "Lorem ipsum dolor sit amet, ...
Stockhouse25d
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for ...
kalkinemedia29d
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates
Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024Protocol being amended to enhance enrollment and lessen burden on participants in t... "Lorem ipsum dolor sit amet, ...